Stock listing
NASDAQ:VTVT vTv Therapeutics Inc. Stock
Home listing (NASDAQ) of vTv Therapeutics Inc.
Follow vTv Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:VTVT
$15.51 USD -0.72 (-4.4%)
Close on Nov 20, 2026
- Day range
- $15.47 – $16.47 USDNov 20, 2026
- Volume
- 10,588 sharesNov 20, 2026
- Market cap
- $61.33M USDAt the close on Nov 20, 2026 · price × 3.95M shares outstanding
- 52-week range
- $15.47 – $44.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $990,961 USDMedian day 22,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VTVT · Home | $15.51 USD | -0.72 (-4.4%) | 10,588 | $15.96 | $16.47 | $15.47 | $16.23 | Close on Nov 20, 2026 |
| Frankfurt:5VT0 | €14.50 EUR | -0.10 (-0.7%) | — | €14.50 | €14.50 | €14.50 | €14.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VTVT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.51 | -0.72 | -4.4% | $15.96 | $16.47 | $15.47 | 10,588 | |
| $16.23 | -1.06 | -6.1% | $16.19 | $16.77 | $16.00 | 21,716 | |
| $17.29 | -0.40 | -2.3% | $16.89 | $18.00 | $16.71 | 26,819 | |
| $17.69 | -2.00 | -10.2% | $19.41 | $19.41 | $17.28 | 20,851 | |
| $19.69 | -1.00 | -4.8% | $20.81 | $20.81 | $19.32 | 17,403 | |
| $20.69 | -0.78 | -3.6% | $21.30 | $21.30 | $20.55 | 70,982 | |
| $21.47 | +0.47 | +2.2% | $21.24 | $21.72 | $21.04 | 11,733 | |
| $21.00 | -0.18 | -0.8% | $21.42 | $22.64 | $20.86 | 24,683 | |
| $21.18 | +0.15 | +0.7% | $21.06 | $21.47 | $20.76 | 13,219 | |
| $21.03 | -0.71 | -3.3% | $21.85 | $22.20 | $20.56 | 14,365 | |
| $21.74 | -2.29 | -9.5% | $23.10 | $23.10 | $21.72 | 17,774 | |
| $24.03 | +0.48 | +2.0% | $23.55 | $24.38 | $23.55 | 28,577 | |
| $23.55 | -0.60 | -2.5% | $22.85 | $25.26 | $22.85 | 37,929 | |
| $24.15 | -1.02 | -4.1% | $24.72 | $24.72 | $23.72 | 20,787 | |
| $25.17 | -1.21 | -4.6% | $25.85 | $26.31 | $24.69 | 14,217 | |
| $26.38 | +0.66 | +2.6% | $26.17 | $27.00 | $25.76 | 41,638 | |
| $25.72 | 0.00 | 0.0% | $25.55 | $25.96 | $25.00 | 17,881 | |
| $25.72 | -0.09 | -0.3% | $26.06 | $26.44 | $25.47 | 11,112 | |
| $25.81 | +0.26 | +1.0% | $25.74 | $26.56 | $25.70 | 14,607 | |
| $25.55 | -1.61 | -5.9% | $27.31 | $27.31 | $25.35 | 21,500 | |
| $27.16 | -0.61 | -2.2% | $27.79 | $28.05 | $27.02 | 10,800 | |
| $27.77 | -0.075 | -0.3% | $28.06 | $29.24 | $27.55 | 14,100 | |
| $27.85 | +0.905 | +3.4% | $27.47 | $28.56 | $27.07 | 21,200 | |
| $26.94 | +0.40 | +1.5% | $26.70 | $27.23 | $26.61 | 17,900 | |
| $26.54 | -1.05 | -3.8% | $27.49 | $27.49 | $25.95 | 11,800 | |
| $27.59 | +0.07 | +0.3% | $27.80 | $28.87 | $27.42 | 22,200 | |
| $27.52 | -0.71 | -2.5% | $27.91 | $28.86 | $27.49 | 20,100 | |
| $28.23 | -2.23 | -7.3% | $30.75 | $31.22 | $27.87 | 41,800 | |
| $30.46 | -0.72 | -2.3% | $31.12 | $31.18 | $30.29 | 17,100 | |
| $31.18 | +1.10 | +3.7% | $30.16 | $31.18 | $30.10 | 12,800 | |
| $30.08 | -0.93 | -3.0% | $31.03 | $31.22 | $29.80 | 44,300 | |
| $31.01 | +0.98 | +3.3% | $29.95 | $31.50 | $29.86 | 26,100 | |
| $30.03 | -0.30 | -1.0% | $30.50 | $30.50 | $29.55 | 27,900 | |
| $30.33 | -0.24 | -0.8% | $31.56 | $31.56 | $30.29 | 14,900 | |
| $30.57 | -1.28 | -4.0% | $32.20 | $32.32 | $30.57 | 18,000 | |
| $31.85 | +1.01 | +3.3% | $30.99 | $32.28 | $30.99 | 34,300 | |
| $30.84 | +0.84 | +2.8% | $30.11 | $31.14 | $29.98 | 30,900 | |
| $30.00 | -0.52 | -1.7% | $30.34 | $30.69 | $30.00 | 85,100 | |
| $30.52 | +0.31 | +1.0% | $29.75 | $31.45 | $29.68 | 111,900 | |
| $30.21 | -0.52 | -1.7% | $30.60 | $30.91 | $29.79 | 28,800 | |
| $30.73 | +0.15 | +0.5% | $30.57 | $31.57 | $30.24 | 18,000 | |
| $30.58 | -0.52 | -1.7% | $31.03 | $31.40 | $30.47 | 18,900 | |
| $31.10 | -0.20 | -0.6% | $31.32 | $32.38 | $31.07 | 11,200 | |
| $31.30 | -0.50 | -1.6% | $31.45 | $32.00 | $31.02 | 22,700 | |
| $31.80 | +0.40 | +1.3% | $31.15 | $32.09 | $31.05 | 74,400 | |
| $31.40 | +0.94 | +3.1% | $30.89 | $32.11 | $30.77 | 33,400 | |
| $30.46 | 0.00 | 0.0% | $30.37 | $30.86 | $29.98 | 91,500 | |
| $30.46 | -0.98 | -3.1% | $31.30 | $31.90 | $29.76 | 45,300 | |
| $31.44 | -0.53 | -1.7% | $31.80 | $32.53 | $31.44 | 22,200 | |
| $31.97 | +0.11 | +0.3% | $32.24 | $32.54 | $31.29 | 13,700 | |
| $31.86 | -1.43 | -4.3% | $33.00 | $33.00 | $31.85 | 46,300 | |
| $33.29 | +0.50 | +1.5% | $32.99 | $34.14 | $32.78 | 39,500 | |
| $32.79 | -0.56 | -1.7% | $33.35 | $33.38 | $32.48 | 28,100 | |
| $33.35 | -0.12 | -0.4% | $32.97 | $33.73 | $32.97 | 12,100 | |
| $33.47 | +0.07 | +0.2% | $33.96 | $33.96 | $32.88 | 20,900 | |
| $33.40 | +1.45 | +4.5% | $32.55 | $34.00 | $32.15 | 39,800 | |
| $31.95 | -0.05 | -0.2% | $31.81 | $32.59 | $31.55 | 52,700 | |
| $32.00 | -0.36 | -1.1% | $32.25 | $32.25 | $31.35 | 94,200 | |
| $32.36 | -0.44 | -1.3% | $32.79 | $33.00 | $31.80 | 90,200 | |
| $32.80 | -0.77 | -2.3% | $33.07 | $34.09 | $32.57 | 58,400 | |
| $33.57 | -0.34 | -1.0% | $33.55 | $34.76 | $32.90 | 117,200 | |
| $33.91 | +0.02 | +0.1% | $33.80 | $34.55 | $33.45 | 59,300 | |
| $33.89 | +0.635 | +1.9% | $33.42 | $34.66 | $32.87 | 18,000 | |
| $33.26 | +0.175 | +0.5% | $33.19 | $33.85 | $32.78 | 26,700 | |
| $33.08 | +0.185 | +0.6% | $32.54 | $33.54 | $31.84 | 62,700 |
Splits
1 split · NASDAQ:VTVT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-40 | Consolidation |
- Ticker
- NASDAQ:VTVT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Mar 10, 2026
Investor Presentation (March 2026)
Investor deck · 25 slides
Latest news
vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026
Closed $21.03 (-3.3%) on Nov 6, 2026
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
Oct 27, 2026
Closed $25.72 (-0.3%) on Oct 27, 2026
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
Oct 10, 2026
Closed $30.46 (-2.3%) on Oct 12, 2026
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
Oct 7, 2026
Closed $30.08 (-3.0%) on Oct 8, 2026
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
Oct 6, 2026
Closed $30.03 (-1.0%) on Oct 6, 2026
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
Oct 5, 2026
Closed $30.33 (-0.8%) on Oct 5, 2026
vTv Therapeutics to Participate in September Investor Conferences
Sep 2, 2026
Closed $33.40 (+4.5%) on Sep 2, 2026
VTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $34.61 (+0.6%) on Aug 6, 2026
VTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
Jun 3, 2026
Closed $32.94 (-0.2%) on Jun 3, 2026
VTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2026
Closed $32.94 (-0.2%) on Jun 3, 2026
vTv Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 103 in all · newest Nov 5, 2026 · oldest 2019
- Decks
- 18 decks · latest Mar 10, 2026
Where vTv Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VTVT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:VTVT | BOATS | United States | USD |
| Frankfurt:5VT0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3EWXG | Lang & Schwarz | Germany | EUR |
| Stuttgart:5VT0 | Stuttgart | Germany | EUR |
| Tradegate:5VT0 | Tradegate | Germany | EUR |
Valuation
EV/sales −0.4× against a median of 12.0×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$15.84M USD
- P/E
- Loss
- EV/sales
- −0.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- Not reported
- Operating margin
- −29.8%
- Net margin
- −20.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| vTv Therapeutics Inc. · NASDAQ:VTVT | US$61.33M | −US$15.84M | n/a | −0.4× | n/a | 0.9× | −20.8% | 0.0× | 1.28 |
| Lytix Biopharma ASA · OSL:LYTIX | US$63.10M | US$53.73M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | n/a |
| Neumora Therapeutics, Inc. · NASDAQ:NMRA | US$63.01M | US$30.65M | n/a | 1,916× | n/a | 3.4× | n/a | 2.9× | 1.07 |
| ViGenCell, Inc. · KRX:308080 | US$61.45M | US$44.89M | n/a | 65.1× | n/a | 2.1× | n/a | 0.2× | n/a |
| Poolbeg Pharma PLC · LSE:POLB | US$61.42M | US$55.12M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Oncopeptides AB · OMXSTO:ONCO | US$61.17M | US$58.97M | n/a | 6.3× | n/a | 25.1× | −223.6% | 5.4× | n/a |
| HemoGenyx Pharmaceuticals PLC · LSE:HEMO | US$60.45M | US$56.88M | n/a | n/a | n/a | 10.7× | n/a | 0.4× | n/a |
| Genexine, Inc. · KRX:095700 | US$60.38M | US$44.48M | n/a | 12.0× | n/a | 0.4× | −650.0% | 0.0× | n/a |
| ISU Abxis Co., Ltd. · KRX:086890 | US$60.20M | US$42.54M | n/a | 1.1× | n/a | 0.7× | −16.0% | 0.0× | n/a |
| GlycoNex, Inc. · TPEX:4168 | US$59.92M | US$57.20M | n/a | 84.9× | n/a | 2.3× | n/a | 0.6× | n/a |
| Rani Therapeutics Holdings, Inc. · NASDAQ:RANI | US$58.99M | US$16.85M | n/a | 2.6× | n/a | 1.7× | −493.0% | 0.1× | 2.21 |
| Median of the others | US$60.81M | US$49.31M | 12.0× | 2.9× | −358.3% | 0.1× | 1.64 |
Forecasts
6 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 56.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.04 · 4 analysts
- Revenue, year to Dec 2026
- 30.73M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Paul Sekhri | Chairman of the Board, President and Chief Executive Officer |
| Rich Nelson | Executive Vice President, Corporate Development |
Board
| Director | Role |
|---|---|
| Paul Sekhri | Chairman of the Board, President and Chief Executive Officer |
| Anne Phillips | Director |
| Daniel K. Spiegelman | Director |
| Fahed Al Marzooqi | Director |
| Raymond Cheong | Lead Independent Director |
| Srinivas Akkaraju | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −3.3% |
| Q2 2026 | Aug 6, 2026 · After close | +2.2% |
| Q1 2026 | May 13, 2026 · After close | +21.4% |
| Q3 2025 | Nov 6, 2025 · After close | +2.2% |
| Q2 2025 | Aug 14, 2025 · After close | +0.9% |
| Q1 2025 | May 15, 2025 · After close | −6.2% |
| Q4 2024 | Mar 11, 2025 · Before open | −2.9% |
| Q3 2024 | Nov 12, 2024 · After close | +7.1% |
| Q2 2024 | Aug 8, 2024 · After close | −1.8% |
| Q1 2024 | May 9, 2024 · After close | −3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 13, 2024 · Before open | +0.4% |
| Q3 2023 | Nov 9, 2023 · After close | −6.8% |
| Q2 2023 | Aug 11, 2023 · After close | +2.6% |
| Q1 2023 | May 11, 2023 · After close | −5.5% |
| Q4 2022 | Mar 6, 2023 · After close | −4.8% |
| Q3 2022 | Nov 10, 2022 · After close | −2.4% |
| Q2 2022 | Aug 15, 2022 · After close | −11.7% |
| Q1 2022 | May 12, 2022 · Before open | −4.7% |
| Q4 2021 | Mar 29, 2022 · After close | +0.3% |
| Quarter to Sep 30, 2021 | Nov 9, 2021 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 25 slides | Mar 10, 2026 |
| Investor Presentation (February 2026) | Investor deck | 25 slides | Feb 26, 2026 |
| Investor Presentation (May 2025) | Investor deck | 19 slides | May 16, 2025 |
| Investor Presentation (March 2025) | Investor deck | 30 slides | Mar 31, 2025 |
| Investor Presentation (January 2025) | Investor deck | 30 slides | Jan 13, 2025 |
| Investor Presentation (March 2024) | Investor deck | 16 slides | Mar 5, 2024 |
| Investor Presentation (November 2023) | Investor deck | 17 slides | Nov 15, 2023 |
| Investor Presentation (January 2023) | Investor deck | 25 slides | Jan 6, 2023 |
| Investor Presentation (August 2020) | Investor deck | 26 slides | August 2020 |
| EASD 2020 | Conference | 17 slides | 2020 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| EASD 2020 | Conference | 15 slides | 2020 |
| Technical Presentation (March 2019) | Technical | 16 slides | Mar 30, 2019 |
| Investor Presentation (February 2019) | Investor deck | 29 slides | Feb 19, 2019 |
| Technical Presentation (October 2018) | Technical | 16 slides | Oct 26, 2018 |
| EASD 2017 | Conference | 15 slides | 2017 |
| Keystone Symposia 2016 | Conference | 10 slides | April 2016 |
| Investor Presentation (November 2015) | Investor deck | 29 slides | Nov 17, 2015 |
| Technical Presentation (July 2015) | Technical | 13 slides | Jul 17, 2015 |
Financings
| Raise | Date |
|---|---|
| Private placement of units of Class A common stock or pre-funded warrants with accompanying warrants Announced: US$80M · US$15.265 a unit · Warrants at US$22.71 · TD Cowen +1 Dealers: TD Cowen (co-lead), Evercore ISI (co-lead) Buyers: Samsara BioCapital, L.P. (existing investor); T1D Fund (existing investor); Trails Edge Capital Partners (new investor); Invus (new investor) Use of proceeds: Fund the ongoing CATT1 Phase 3 trial and continued development of cadisegliatin for type 1 diabetes | Sep 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Jul 29, 2015.
- Price
- US$15.00 a share
- Shares offered
- 7,812,500 shares of Class A common stock
- Offering size
- US$117.2 million
- Underwriters
- Piper Jaffray, Stifel, Canaccord Genuity, Janney Montgomery Scott · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2015 |
| Filed publicly | Jun 15, 2015 |
| Amended 6 times | Newest Jul 24, 2015 |
| Declared effective by the SEC | Jul 29, 2015 |
| Shares registered with an exchange | Jul 30, 2015 |
| Final prospectus, with the price | Jul 31, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 31, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Jul 30, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 30, 2015 |
| EFFECT · Notice that a registration is effective | Jul 29, 2015 |
| CORRESP · Letter to the SEC | Jul 28, 2015 |
| S-1/A · Registration statement, amended | Jul 24, 2015 |
| UPLOAD · Letter from the SEC | Jul 24, 2015 |
| S-1/A · Registration statement, amended | Jul 23, 2015 |
| FWP · Free writing prospectus | Jul 20, 2015 |
| FWP · Free writing prospectus | Jul 20, 2015 |
All 25 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jul 20, 2015 |
| CORRESP · Letter to the SEC | Jul 14, 2015 |
| CORRESP · Letter to the SEC | Jul 13, 2015 |
| S-1/A · Registration statement, amended | Jul 13, 2015 |
| UPLOAD · Letter from the SEC | Jul 10, 2015 |
| UPLOAD · Letter from the SEC | Jul 8, 2015 |
| CORRESP · Letter to the SEC | Jul 8, 2015 |
| CORRESP · Letter to the SEC | Jul 6, 2015 |
| S-1/A · Registration statement, amended | Jul 2, 2015 |
| UPLOAD · Letter from the SEC | Jun 30, 2015 |
| S-1/A · Registration statement, amended | Jun 19, 2015 |
| S-1 · Registration statement | Jun 15, 2015 |
| UPLOAD · Letter from the SEC | Jun 11, 2015 |
| DRSLTR · Letter to the SEC with a draft | May 14, 2015 |
| DRS · Draft registration statement | May 14, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 31, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.02M | 0 | 2.02M | 4.00M | 6.41M | 2.76M | 12.4M | 291.0K | 634.0K |
| Cost of revenue | 16.0K | 89.0K | 90.0K | 92.0K | 89.0K | 11.0M | 15.1M | 23.0M | 39.6M | 45.7M |
| Gross profit | -16.0K | 1.02M | -90.0K | 2.02M | 4.00M | -4.60M | -12.4M | -10.6M | -39.3M | -45.1M |
| Research and development | 17.9M | 11.5M | 13.6M | 12.4M | 13.3M | 11.0M | 15.1M | 23.0M | 39.6M | 45.0M |
| Selling, general and administrative | 14.9M | 13.7M | 11.9M | 12.2M | 12.3M | 7.25M | 8.54M | 9.22M | 11.3M | 9.91M |
| Operating income | -32.8M | -24.2M | -25.5M | -22.5M | -21.7M | -11.9M | -20.9M | -19.8M | -50.7M | -55.0M |
| Depreciation and amortization | 16.0K | 89.0K | 90.0K | 92.0K | 89.0K | 94.0K | 39.0K | 218.0K | 197.0K | 265.0K |
| EBITDA | -32.8M | -24.1M | -25.4M | -22.4M | -21.6M | -11.8M | -20.9M | -19.6M | -50.5M | -54.8M |
| Interest expense | 6.00K | 0 | 13.0K | 15.0K | 12.0K | 692.0K | 1.83M | 3.29M | 3.09M | 398.0K |
| Income before tax | -31.1M | -22.6M | -26.0M | -24.9M | -17.6M | -12.8M | -21.8M | -23.6M | -53.8M | -55.4M |
| Income tax | 0 | 100.0K | 0 | 200.0K | 115.0K | 0 | 100.0K | 200.0K | 800.0K | 0 |
| Net income | -27.0M | -18.5M | -20.3M | -19.2M | -13.0M | -8.50M | -13.0M | -7.91M | -16.1M | -16.4M |
| Earnings per share, basic | -3.20 | -3.20 | -9.71 | -9.98 | -8.29 | -7.21 | -17.22 | -25.42 | -66.62 | -1.71 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 88.9M | 36.7M | 9.45M | 12.1M | 13.4M | 5.75M | 1.78M | 1.68M | 11.8M | 51.5M |
| Short-term investments | 85.0K | 65.0K | 15.0K | 100.0K | 371.0K | 250.0K | 1.12M | 162.0K | 0 | |
| Receivables | 62.0K | 102.0K | 173.0K | 57.0K | 158.0K | 5.00K | 0 | 8.00M | 0 | |
| Inventory | 15.0K | 100.0K | 371.0K | 250.0K | 162.0K | 0 | ||||
| Current assets | 89.9M | 38.1M | 10.7M | 27.1M | 15.6M | 7.21M | 2.84M | 3.47M | 20.4M | 52.1M |
| Property, plant and equipment | 28.0K | 117.0K | 207.0K | 278.0K | 367.0K | 461.0K | 70.0K | 283.0K | 444.0K | |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 89.9M | 38.3M | 11.0M | 33.2M | 25.5M | 14.8M | 9.27M | 8.56M | 27.9M | 54.5M |
| Accounts payable | 1.13M | 939.0K | 4.08M | 2.46M | 1.88M | 1.93M | 2.23M | 2.90M | 2.27M | 3.06M |
| Current liabilities | 6.64M | 5.20M | 10.6M | 7.71M | 8.50M | 6.39M | 13.4M | 18.8M | 26.9M | 11.4M |
| Long-term debt | 6.33M | 15.3M | 11.1M | |||||||
| Total debt | 169.0K | 529.0K | 716.0K | 932.0K | 915.0K | 5.18M | 15.3M | 19.6M | 11.1M | |
| Total liabilities | 25.5M | 24.0M | 29.6M | 27.4M | 10.3M | 11.0M | 18.1M | 28.9M | 47.5M | 22.9M |
| Shareholders' equity | 64.4M | 12.2M | -24.7M | -10.7M | -9.74M | -80.1M | -49.0M | -82.9M | -151.0M | -90.9M |
| Shares outstanding | 8.42M | 5.77M | 2.08M | 1.92M | 1.57M | 1.18M | 757.3K | 311.2K | 242.3K | 9.55M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -25.3M | -25.3M | -19.1M | -16.0M | -19.3M | -18.0M | -23.0M | -26.9M | -44.6M | -48.2M |
| Capital spending | 0 | 0 | 0 | -21.0K | 0 | 0 | -70.0K | -5.00K | -57.0K | -87.0K |
| Free cash flow | -25.3M | -25.3M | -19.1M | -16.0M | -19.3M | -18.0M | -23.1M | -26.9M | -44.6M | -48.3M |
| Cash from investing | 0 | 0 | 4.40M | -21.0K | 0 | 0 | 242.0K | 7.00K | -25.0K | -83.0K |
| Cash from financing | 77.4M | 52.6M | 12.0M | 14.8M | 27.0M | 19.5M | 22.9M | 16.6M | 7.50M | 11.8M |
| Dividends paid | -992.0K | 0 | 0 | |||||||
| Share buybacks | 9.75M | 14.4M | 992.0K | 21.5M | 302.0K | 923.0K | ||||
| Change in cash | 52.2M | 27.3M | -2.68M | -1.29M | 7.67M | 1.47M | 94.0K | -10.2M | -37.1M | -36.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 29, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 10, 2026 | Meeting notice | SEC |
| 424B2 · Prospectus | May 13, 2026 | Offer document | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2026 | Material contract | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 9, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| S-3 · Registration statement | Oct 3, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 2, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 21, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Management or board change | SEC |
| 8-K · Current report | May 16, 2025 | Current report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 144 · Notice of proposed sale | May 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 24, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Apr 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 11, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 8-K · Current report | Mar 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 25, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 23, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 26, 2024 | Current report | SEC |
| 8-K · Current report | Jul 2, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2024 | Other filings | SEC |
| 424B2 · Prospectus | Apr 29, 2024 | Offer document | SEC |
| 424B2 · Prospectus | Apr 29, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 16, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 10, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 26, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 22, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 14, 2024 | Management or board change | SEC |
| 10-K · Annual report | Mar 13, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 7, 2024 | Insider trade | SEC |
| D | Mar 7, 2024 | Other filings | SEC |
| SC 13D · Big-stake notice | Mar 5, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Mar 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 5, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Feb 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 28, 2024 | Results | SEC |
| 424B5 · Prospectus | Feb 28, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 28, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 22, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 19, 2023 | Current report | SEC |
| 8-K · Current report | Dec 12, 2023 | Current report | SEC |
| 8-K · Current report | Nov 20, 2023 | Current report | SEC |
| 8-K · Current report | Nov 15, 2023 | Current report | SEC |
| 8-K · Current report | Nov 15, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| 8-K · Current report | Nov 1, 2023 | Acquisition or disposal | SEC |
| DEF 14C | Sep 25, 2023 | Meeting notice | SEC |
| PRE 14C | Sep 15, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 8-K · Current report | Jul 20, 2023 | Current report | SEC |
| 8-K · Current report | Jun 26, 2023 | Current report | SEC |
| 4/A · Change in ownership, amended | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| DEF 14A · Proxy statement | Apr 26, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 6, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2023 | Results | SEC |
| 3 · Initial statement of ownership | Mar 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 1, 2023 | Current report | SEC |
| 8-K · Current report | Jan 6, 2023 | Current report | SEC |
| 8-K · Current report | Dec 23, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 13, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 13, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| SC 13G · Big-stake notice | Aug 23, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 18, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 17, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 8-K · Current report | Aug 15, 2022 | Management or board change | SEC |
| 3 · Initial statement of ownership | Aug 8, 2022 | Insider trade | SEC |
| 8-K · Current report | Jul 27, 2022 | Management or board change | SEC |
| 8-K · Current report | Jul 25, 2022 | Material contract | SEC |
| 4 · Change in ownership | Jul 15, 2022 | Insider trade | SEC |
| 8-K · Current report | Jul 15, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Jul 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2022 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jun 10, 2022 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 10, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2022 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 1, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jun 1, 2022 | Material contract | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | May 2, 2022 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2022 | Management or board change | SEC |
| 10-K/A · Annual report, amended | Apr 5, 2022 | Annual report | SEC |
| 8-K · Current report | Apr 5, 2022 | Management or board change | SEC |
| 10-K · Annual report | Mar 29, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 29, 2022 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2022 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2022 | Management or board change | SEC |
| 8-K · Current report | Feb 18, 2022 | Current report | SEC |
This page holds 200 of 603 filings. Open Filings
Cap table
Built by 6ix from vTv Therapeutics Inc.’s releases · as of Sep 2, 2025
- Common shares
- 3,953,928
- Fully diluted
- 3,953,928
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,953,928 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,953,928 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Srinivas Akkaraju Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Alumis Inc. (Founder and Managing Member, Samsara BioCapital · Since at least Jun 27, 2024); Mineralys Therapeutics, Inc. (Board Member · Since at least Feb 9, 2023); Scholar Rock Holding Corporation (Director · Since at least Jul 26, 2022); Jiya Acquisition Corp (Director · Sep 23, 2022 – Sep 23, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 1, 2022 – Sep 16, 2024 · Past); Aduro Biotech Inc (Director · May 26, 2022 – Aug 11, 2023 · Past); Intercept Pharmaceuticals Inc (Director · May 25, 2022 – Nov 8, 2023 · Past) | Director · Since at least Feb 23, 2024 |
| Paul Sekhri Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Veeva Systems Inc. (Director · Since at least Jun 22, 2016); Axcella Health Inc (Director · May 19, 2022 – May 19, 2022 · Past); Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past); BiomX Inc. (Director · Oct 2, 2020 – Jul 28, 2021 · Past); Enumeral Biomedical Holdings Inc (Director · Dec 9, 2016 – Dec 9, 2016 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Jan 2, 2020 · Past) | Chairman of the Board, President and Chief Executive Officer · Since at least Aug 1, 2022 |
| Paul G Savas Other companies: Revlon Inc (Director · Jun 9, 2016 – Nov 11, 2016 · Past); SIGA Technologies Inc. (Director · May 23, 2012 – Jun 16, 2020 · Past); M & F Worldwide Corp (Executive Vice President & CFO · Dec 21, 2011 – Dec 21, 2011 · Past) | Director · Jul 30, 2015 – Sep 6, 2018 · Past |
| Edward P Taibi Other companies: Archaea Energy Inc (GC, EVP Strat Init & Gov Aff · Mar 21, 2022 – Dec 28, 2022 · Past); SIGA Technologies Inc. (Director · Aug 6, 2020 – Aug 6, 2020 · Past) | Director · Aug 31, 2020 – Aug 31, 2020 · Past |
| Deepa Prasad Other companies: Design Therapeutics, Inc. (Director · Since at least Jun 15, 2021) | President and CEO, Director · Oct 19, 2021 – Oct 19, 2021 · Past |
| Keith R. Harris Other companies: MeiraGTx Holdings plc (Chairman of the Board · Since at least Jun 8, 2018) | Director · Jul 11, 2022 – Jun 19, 2023 · Past |
| Anne Phillips | Director · Since at least Nov 5, 2026 |
| Barry K Brown | Chief Accounting Officer · Apr 11, 2025 – Apr 11, 2025 · Past |
| Chandresh Harjivan | Director · Jun 1, 2022 – Jun 19, 2023 · Past |
| Daniel K. Spiegelman | Director · Since at least Nov 5, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Fahed Al Marzooqi | Director · Since at least Nov 5, 2026 |
| Howard L Weiner | Director · Jul 31, 2017 – Jun 19, 2023 · Past |
| Martin Lafontaine | Chief Commercial Officer · Mar 20, 2025 – Nov 5, 2026 · Past |
| Michael Tung | Executive Vice President and Chief Financial Officer · May 19, 2025 – Nov 5, 2026 · Past |
| Raymond Cheong | Lead Independent Director · Since at least Nov 5, 2026 |
| Rich Nelson | Executive Vice President, Corporate Development · Since at least Feb 2, 2026 |
| Stephen L Holcombe | President & CEO · Jul 30, 2015 – Dec 7, 2020 · Past |
Log in to ask 6ix AI your own questions about vTv Therapeutics Inc.